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Prostate cancer is the second most common male malignancy in Poland. We present guidelines of Polish and inter-
national oncology and urology societies on hormonal therapy for localized prostate cancer.
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Introduction
Prostate cancer is the second most frequent male malig-
nancy in Poland [1]. The incidence has increased worldwide 
over recent decades, mainly due to aging of the population 
and growing tendency for measuring the prostate-specific 
antigen (PSA) levels. The management of prostate cancer 
requires a close collaboration between urologist, clinical 
oncologist and radiation oncologist to choose the most suit-
able therapeutic strategy considering tumor stage, the pa-
tient’s general health status and his individual preferences. 
Evidence-based therapeutic recommendations published 
by Polish and international societies for oncology and urol-
ogy aim at improving treatment efficacy. The 5-year survival 
rates for prostate cancer patients in Poland are merely 67% 
compared to European average of 83% [2]. The only three 
European Union countries with poorer outcomes are Bul-
garia, Slovakia and Latvia.
Prostate cancer is primarily hormone-dependent. This 
article provides recommendations from the largest societies 
for urology and oncology on hormone therapy (HT) in local-
ized prostate cancer. The only recommendations available 
in Poland in this area were published in 2013 by the Polish 
Society of Clinical Oncology (PTOK) [3]. This document is 
mainly based on the European Association of Urology (EUA) 
guidelines, which were later updated in 2015 [4]. Other 
guidelines addressed in this article are those developed in 
2007 by the American Urological Association (AUA; updated 
in 2011) [5], last year’s recommendations from the European 
Society for Medical Oncology (ESMO) [6], version 1.2016 of 
the National Comprehensive Cancer Network (NCCN) in the 
US [7], and the guidelines of the British National Institute for 
Health and Clinical Excellence (NICE) from 2014 [8].
The article refers to low, intermediate and high risk prostate 
cancer prognostic groups, considering the local tumor extent 
according to the TNM staging system, cancer grade according 
to the Gleason score (GS) and the highest PSA level (Tab. I).
General principles of hormone therapy
HT for prostate cancer aims at inhibiting the stimulatory 
effect of circulating male hormones on cancer cells. This may 
be achieved by reducing androgen secretion by surgical or 
pharmacological castration, or by competitive inhibition of 
androgens binding to their receptors by means of anti-an-
drogen therapy. The effectiveness of HT in achieving castra-
tion blood levels of testosterone is judged to be < 50 ng/dL 
(1.7 nmol/L). The EUA is the only society that refers to gen-
eral principles of HT and suggests moving the cut-off limit 
to 20 ng/dL (1 nmol/L), which is justified by the increased 
sensitivity of currently used laboratory methods [4].
The main adverse reactions of HT are cardiovascular 
toxicity (increased risk of heart attack), sexual function 
(decreased libido, erectile dysfunction), increased risk of 
pathological fracture, fatigue, hot flushes, depressed mood 
and metabolic disorders (such as insulin resistance).
404
Hormonal therapies in prostate cancer
GnRH analogues (LHRH, luteinizing hormone 
releasing hormone) and others like goserelin, 
leuprorelin, triptorelin
These are the most common compounds used in HT, and 
are administered by subcutaneous or intramuscular injec-
tion every 1–6 months. The first dose stimulates pituitary 
receptors, leading to transient increase of testosterone lev-
els, which appears after 2–3 days and lasts for about a week. 
Castration concentrations of testosterone are achieved in 
approximately 90% of patients, usually after 2–4 weeks [9]. 
Initial rise of testosterone level may temporally worsen the 
symptoms, particularly in patients with a large prostate 
volume (urinary retention, acute non-renal kidney damage), 
massive bone metastases (bone pain, spinal cord compres-
sion) or cause sudden cardiovascular events (e.g. sudden 
cardiac death due to hyper-coagulation).
LHRH antagonists (degarelix)
These drugs block directly LHRH receptors in the pi-
tuitary gland and immediately reduce the circulating lev-
els of testosterone. The main drawback is that they are 
short-lasting forms. These compounds are recommended 
for induction treatment in patients with increased risks of 
complications following use of LHRH analogues.
Anti-androgens
These orally administered compounds are divided 
according to their chemical structure into steroid (cypro-
terone acetate) and nonsteroid (bicalutamide, flutamide, 
nilutamide) derivatives. The nonsteroidal types have no 
effect on circulating testosterone levels. Steroid derivatives 
penetrate the blood-brain barrier and also inhibit centrally 
testosterone secretion. The adverse side effects include 
cardiovascular toxicity and hepatotoxicity. At the start of 
HT these drugs are usually combined with LHRH analogues 
to reduce the severity of side effects accompanying the 
transient testosterone peaking. The combination of an 
anti-androgen and an LHRH analogue is termed complete 
androgen blockade (CAB).
Published recommendations provide scant informa-
tion about making preferred choices of HT agents for pros-
tate cancer. PTOK, NCCN and NICE all agree that using CAB 
should not be considered a standard treatment [3, 7, 8]. 
In addition, PTOK and NICE do not recommend using 
anti-androgens as a monotherapy [3,7]; according to the 
PTOK this concerns T1a-2c grades. For patients with high 
risk of relapse undergoing combination therapy including 
radiation therapy (RT) and HT, PTOK recommends using 
LHRH analogs [3].
Hormone therapy as the sole treatment modality
All urology and oncology societies point out that HT 
alone in patients with non-metastatic prostate cancer, 
including patients at old age and with major medical co-
morbidities, should not be considered as a standard pro-
cedure [3–8].
A separate subgroup include patients who withhold 
consent or are ineligible for radical treatment due to co-
morbidities. Urology societies and ESMO recommend in 
this group HT to relieve troublesome symptoms, such as 
urinary retention [4, 5, 6] (Tab. II). Moreover, the EUA pro-
poses delayed HT in: asymptomatic T3–4 patients, with 
PSA doubling time (PSA DT) less than 12 months, with PSA 
over 50 ng/mL, and with poorly differentiated tumour [4]. 
The PTOK allows HT (other than anti-androgens) in patients 
with cancer symptoms and with a PSA DT < 12 months or 
PSA > 25–50 ng/mL [3]. The NCCN defines a group of very 
high risk patients, ineligible for radical treatment who may 
benefit from the use of HT alone by the following features: 
(i) T3b–4, (ii) a primary GS of 5, or (iii) total GS of ≥ 8 in ≥ 4 
biopsy specimens [7].
In patients ineligible for radical treatment the use of HT 
alone should take into account possible adverse reactions, 
which may outweigh the expected benefits (AUA) [5].
Patients with pelvic lymph node metastases at presenta-
tion should receive HT in combination with RT (according to 
PTOK, EUA and NCCN), or as a sole modality (NCCN) [3, 4, 7].
Hormone therapy as an adjunct  
to radical prostatectomy 
Preoperative HT
EAU, NCCN, PTOK, AUA do not recommend using HT 
before radical prostatectomy [3, 4, 5, 7].
Table I. Prognostic groups of patients with localised prostate cancer
Low risk Intermediate risk High risk
PSA < 10 ng/mL PSA 10–20 ng/mL PSA > 20 ng/mL Any PSA
and GS < 7 or GS = 7 or GS > 7 Any GS
and cT1–2a or cT2b or cT2c cT3–4 or cN+
                                                                        Localised Local or regional advancement
GS — Gleason score; PSA — prostate specific antigen
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Hormone therapy after surgery (Tab. III)
According to the PTOK, EUA, NCCN and NICE guidelines, 
patients after radical prostatectomy without lymph node 
metastases should not receive adjuvant HT, regardless of 
local advancement, positive margins or other unfavorable 
prognostic features [3, 4, 7, 8].
Whenever lymph node metastases are histologically 
confirmed after radical prostatectomy, the EUA and NCCN 
recommend routine use of HT [4, 7]. According to the EUA, 
treatment in this group may be deferred until PSA levels 
have risen in patients who underwent extended lymph 
node dissection (eLND), with microscopic metastases no 
more than two lymph nodes (without extranodal invasion) 
and with a postoperative PSA of < 0.1 ng/mL, provided they 
are subjected to active surveillance [4]. PTOK guidelines 
recommend starting HT only in patients with at least two 
lymph nodes involved [3].
Hormone therapy in combination  
with radiotherapy 
According to all the aforementioned guidelines, low-risk 
patients should receive RT without HT and intermediate-risk 
patients should be considered for RT combined with HT 
lasting for 4–6 months (Tab. IV) [3–8]. In patients selected 
for combined treatment, special attention should be paid 
towards the comorbidities which may reduce the expected 
benefit of systemic treatment. Apart from NICE, all societies 
recommend starting HT before RT (although the EUA also 
allows for both treatments to be launched simultaneous-
ly) [4] and for continuing HT during and after RT for 4– 
–6 months [3–7]. NICE recommends using HT before, during 
or after the RT [8].
In patients with a significant history of medical comor-
bidities or in those not consenting to HT due to possible 
complications (e.g. sexual dysfunctions), the EUA and AUA 
permit the exclusive use of RT at escalated doses [4, 5]. In 
high risk patients (i.e. very high risk or loco-regional ad-
vancement, depending on the terminology used in the 
guidelines) all societies, apart from NICE, recommend com-
bining RT with long-term HT (2–3 years) [3–7]. NICE recom-
mends that extending the duration of HT for more than 
6 months should be discussed with the patient [8]. EUA 
points out that extending HT for over 6 months to 2–3 years 
should consider patient’s health status, comorbidities and 
any adverse prognostic factors, such as local advancement 
≥ T2C, GS ≥ 8, PSA > 20 ng/mL [4]. Expected survival time 
Table II. Indications for hormonal therapy in patients with localised prostate cancer, withholding consent or ineligible for radical treatment due to 
non-oncological comorbidities
Society Indications
EUA  — Patients with clinical symptoms
 — Patients without clinical symptoms and:
•	 cT3–4 and
•	 PSA DT < 12 months and
•	 PSA > 50 ng/mL and
•	 poorly differentiated grade
AUA Patients with clinical symptoms and locally advanced cancer or a poorly differentiated tumour
ESMO Patients with clinical symptoms
PTOK Patients with clinical symptoms and:
 — PSA DT < 12 months or
 — PSA > 25–50 ng/mL
NCCN  — cT3b-4 or
 — primary GS 5 or
 — total GS ≥ 8 in ≥ 4 biopsy specimens
EUA — European Association of Urology; AUA — American Urological Association; ESMO — European Society for Medical Oncology; PTOK — Polish Society for Clinical 
Oncology; NCCN — National Comprehensive Cancer Network; GS — Gleason score; PSA — prostate specific antigen; PSA DT — PSA doubling time
Table III. Indications for adjuvant hormonal therapy after radical prostatectomy in non-metastatic prostate cancer patients
Category EUA PTOK NICE NCCN
pN0 No HT No HT No HT No HT
pN+ HT, with deferring HT until biochemical relapse in patients post eLND,  
with ≤ 2 involved lymph nodes and PSA level < 0.1 ng/mL
HT if ≥ 2 nodes HT
NICE — National Institute for Health and Clinical Excellence; eLND — extended lymph node dissection; HT — hormone therapy
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and complication risk should be taken into account in elderly 
patients with significant comorbidities, since they may not 
benefit from combining RT and HT (EUA) [4].
Owing to the absence of dedicated randomized tri-
als, special considerations apply to patients administered 
proton radiotherapy. Hence, this treatment should follow 
photon RT (EUA) [4].
Hormone therapy in patients with biochemical 
relapse after curative local treatment (Tab. V)
The definition of biochemical relapse after prostatec-
tomy includes two PSA measurements of > 0.2 ng/mL, with 
a rising trend [10], whereas biochemical relapse after radical 
RT is defined as increasing PSA levels by ≥ 2 ng/mL com-
pared to the lowest post-radiotherapy levels [11].
Due to the lack of strong supporting evidence, the role 
of HT after curative local treatment is still a matter of debate 
and therapeutic decisions are based on individual/case-by-
case approach [4, 7]. According to all guidelines (Tab. V), 
a biochemical relapse after radical prostatectomy is not an 
indication for immediate HT [4, 6–8]. In patients with a short 
PSA DT and long expected survival, the NCCN guidelines 
suggest considering early launching of intermittent HT [7]. 
The EUA does not recommend using HT in asymptomatic 
patients and in patients with a long (> 12 months) PSA DT [4]. 
According to the NCCN, HT is indicated in patients with 
a high probability of distant metastases, irrespective of 
whether salvage RT is used [7]. The NICE and ESMO guide-
lines include three indications for administering HT after 
radical prostatectomy: symptomatic disease, confirmed 
distant metastases and a PSA DT < 3 months [6, 8].
HT at biochemical relapse after radical RT is also indi-
cated in patients not eligible to salvage treatment (EUA) [4]. 
EUA and ESMO suggest using an intermittent regimen for 
such patients [4, 6], whilst the NCCN recommends watch-
ful waiting or immediate application of HT, depending on 
individual risk of relapse [7].
Conclusions
The presented evidence-based guidelines demonstrate 
relative uniformity regarding the most important indications 
for the use of HT in patients with localized prostate cancer. 
Their widespread implementation might improve treatment 
outcomes of this entity in Poland.
Table V. Considerable indications for hormone therapy in patients with biochemical relapse after radical treatment
Society Indications
EUA  — PSA DT < 12 months — to be considered
 — No possibility of salvage treatment after radical RT, considering risk factor
NCCN  — Short PSA doubling time (PSA DT) and long expected survival
  — High risk of distant metastases
NICE  — Symptomatic local progression 
 — PSA DT £ 3 months
ESMO  — Symptomatic local progression 
 — PSA DT £ 3 months
PSA — prostate specific antigen; PSA DT — PSA doubling time; RT — radiotherapy
Table IV. Recommendations for combining hormone therapy with radiotherapy in patients with localised prostate cancer
Society Low risk Intermediate risk High risk/ local or regional advancement
EUA RT alone RT + HT 4–6 months  
if no contraindications 
RT + HT 2–3 years 
(if no contraindications)
PTOK RT alone RT + HT 4–6 months in patients with 
unfavourable prognostic factors
RT + HT 2–3 years
ESMO RT alone RT ± HT 4–6 months RT + HT 2–3 years
NICE RT alone RT + HT 6 months RT + HT ≥ 6 months; extension to 3 years  
should be considered
AUA RT alone RT + HT 6 months RT + HT 2–3 years
NCCN RT alone RT ± HT 4–6 months RT + HT 2–3 years
(if no contraindications)
RT — radiotherapy; HT — hormone therapy
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